GLP1 agonists beyond glycemic control-redefining their role

被引：3

作者：

Chowdhury, Subhankar ^{[1
]}

Goswami, Soumik ^{[2
]}

机构：

[1] IPGME&R & SSKM Hosp, Dept Endocrinol & Metab, 244 AJC Bose Rd, Kolkata 700020, India

[2] Nilratan Sircar Med Coll, Dept Endocrinol, Kolkata, India

来源：

INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES | 2020年 / 40卷 / 04期

关键词：

PEPTIDE-1 RECEPTOR AGONISTS; EXENDIN-4; INCRETIN; ANALOG;

D O I：

10.1007/s13410-020-00879-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：461 / 463

页数：3

共 26 条

[1]

[Anonymous], 2008, Diabetes Mellitus-Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes Guidance for Industry

[2] Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations [J].

Arrese, Marco ;

Barrera, Francisco ;

Triantafilo, Nicolas ;

Pablo Arab, Juan .

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 13 (09) :849-866

[3] Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study [J].

Astrup, Arne ;

Rossner, Stephan ;

Van Gaal, Luc ;

Rissanen, Aila ;

Niskanen, Leo ;

Al Hakim, Mazin ;

Madsen, Jesper ;

Rasmussen, Mads F. ;

Lean, Michael E. J. .

LANCET, 2009, 374 (9701) :1606-1616

[4] Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial [J].

Athauda, Dilan ;

Maclagan, Kate ;

Skene, Simon S. ;

Bajwa-Joseph, Martha ;

Letchford, Dawn ;

Chowdhury, Kashfia ;

Hibbert, Steve ;

Budnik, Natalia ;

Zampedri, Luca ;

Dickson, John ;

Li, Yazhou ;

Aviles-Olmos, Iciar ;

Warner, Thomas T. ;

Limousin, Patricia ;

Lees, Andrew J. ;

Greig, Nigel H. ;

Tebbs, Susan ;

Foltynie, Thomas .

LANCET, 2017, 390 (10103) :1664-1675

[5] Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials [J].

Buse, John B. ;

Klonoff, David C. ;

Nielsen, Loretta L. ;

Guan, Xuesong ;

Bowlus, Christopher L. ;

Holcombe, John H. ;

Maggs, David G. ;

Wintle, Matthew E. .

CLINICAL THERAPEUTICS, 2007, 29 (01) :139-153

[6] Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019 [J].

Cefalu, William T. ;

Berg, Erika Gebel ;

Saraco, Mindy ;

Petersen, Matthew P. ;

Uelmen, Sacha ;

Robinson, Shamera .

DIABETES CARE, 2019, 42 :S90-S102

[7] The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity [J].

Crane, James ;

McGowan, Barbara .

THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2016, 7 (02) :92-107

[8] External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals [J].

Cuthbertson, Daniel J. ;

Weickert, Martin O. ;

Lythgoe, Daniel ;

Sprung, Victoria S. ;

Dobson, Rebecca ;

Shoajee-Moradie, Fariba ;

Umpleby, Margot ;

Pfeiffer, Andreas F. H. ;

Thomas, E. Louise ;

Bell, Jimmy D. ;

Jones, Helen ;

Kemp, Graham J. .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2014, 171 (05) :561-569

[9]

Delgado-Aros S, 2002, AM J PHYSIOL-GASTR L, V282, pG424

[10] The Glucagon-Like Peptide 1 (GLP-1) Analogue, Exendin-4, Decreases the Rewarding Value of Food: A New Role for Mesolimbic GLP-1 Receptors [J].

Dickson, Suzanne L. ;

Shirazi, Rozita H. ;

Hansson, Caroline ;

Bergquist, Filip ;

Nissbrandt, Hans ;

Skibicka, Karolina P. .

JOURNAL OF NEUROSCIENCE, 2012, 32 (14) :4812-4820

← 1 2 3 →